The company said it will use the funds to expand its operations in Ireland, which it established through the recent acquisition of Genomics Medicine Ireland.
WuXi's data analysis tools will be hosted on Google's Cloud marketplace while Google's genomics and research tools will be integrated with WuXi's platform.
Some of the biggest players in the life science tools and diagnostics industries including Danaher, Agilent, and Hologic presented on day two of the conference, discussing plans for 2018.
Rhythm is using WuXi's artificial intelligence capabilities to support drug development targeting pathways associated with genetic obesity syndromes.
As of this week, the project had sequenced 39,500 genomes and returned reports for about 3,000 rare disease families and more than 600 cancer patients.
With the cash, WuXi NextCode will build out its AI and deep learning, seek partnerships in precision medicine and diagnostics, and commercialize genomic tests.
The new funds will help WuXi NextCode advance and commercialize genomic tests for the Chinese market, and strengthen its position in informatics.
At the ACMG annual conference in Phoenix last week, several labs and companies discussed their efforts in healthy genome sequencing.
The New York Times Magazine examines gender discrimination at the Salk Institute.
Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.
A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.
In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.